Stay updated with breaking news from Neurosense. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A statistically significant, 37.4% difference (P=0.03), slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo, in the. ....
NeuroSense Therapeutics Ltd. (NRSN) announced Tuesday that it met its primary safety and tolerability endpoints and achieved secondary clinical efficacy endpoints in the top-line results of its 6-month, randomized, placebo-controlled, double-blind segment the Company's Phase 2b amyotrophic lateral sclerosis (ALS) trial of PrimeC (PARADIGM). ....
/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for neurodegenerative diseases, today announced it. ....
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced scientific presentations at three upcoming conferences. ....
/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today. ....